drugset / Trial / NCT01084330

Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

NCT01084330

Phase 2 Completed 68 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

A clinical trial to determine the effectiveness and safety of AUY922 compared to other drugs known to be effective against gastric cancer in second line therapy for patients who have failed one line of chemotherapy.

Timeline

Start
2010-04
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AUY922 Small molecule 70 mg/m2
Comparator Docetaxel Small molecule 75 mg/m2
Comparator Irinotecan Small molecule 350 mg/m2